NOBL vs XBI
ProShares S&P 500 Dividend Aristocrats ETF vs SPDR S&P Biotech ETF
- • NOBL pays a higher dividend yield (1.98%).
Side-by-side metrics
| Metric | NOBL | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.35% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.98% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $11.90B | $10.92B |
YTD return | 18.41% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.52 | 1.01 |
P/E ratio | 21.73 | — |
Last price | $60.53 | $156.41 |
Inception | — | — |
Issuer | ProShares | State Street |
NOBL top holdings
| ROP | Roper Technologies Inc | 1.91% |
| FDS | FactSet Research Systems Inc | 1.85% |
| BDX | Becton Dickinson & Co | 1.78% |
| IBM | International Business Machines Corp | 1.73% |
| ERIE | Erie Indemnity Co Class A | 1.71% |
| CVX | Chevron Corp | 1.68% |
| XOM | ExxonMobil Holdings Corp | 1.67% |
| ADP | Automatic Data Processing Inc | 1.67% |
| EMR | Emerson Electric Co | 1.63% |
| MDT | Medtronic PLC | 1.63% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About NOBL
NOBL (ProShares S&P 500 Dividend Aristocrats ETF) is S&P 500 names with 25+ years of dividend growth. Managed by ProShares, the fund carries $11.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 1.98%. Its largest holding is Roper Technologies Inc (ROP), which represents 1.9% of the portfolio. Real Estate is the fund's largest sector exposure at 3.7%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.